Name
GS3-04A - Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the Phase III CAPItello-291 trial
Date & Time
Wednesday, July 6, 2022
Speakers
Virtual Session Link